Literature DB >> 7114840

Pharmacokinetics of cefonicid, a new broad-spectrum cephalosporin.

S L Barriere, G J Hatheway, J G Gambertoglio, E T Lin, J E Conte.   

Abstract

This study determined the pharmacokinetic disposition of cefonicid. A single dose of 7.5 mg/kg of body weight was administered to five healthy volunteers as a 5-min intravenous infusion. Multiple plasma and urine samples were collected for 48 h. Peak plasma concentrations ranged from 95 to 156 micrograms/ml and fell slowly (mean plasma half-life, 4.4 +/- 0.8 h), so that levels after 12 h were in the range of 6 to 12 micrograms/ml. Urinary concentrations were high but variable and ranged from 100 to 1,000 micrograms/ml for the first 12 h after the dose and averaged 84 micrograms/ml between 12 and 24 h. Plasma and renal clearances were 0.32 +/- 0.06 and 0.29 +/- 0.05 ml/min per kg, respectively. An average of 88 +/- 6% of the dose was excreted unchanged in the urine over 48 h. The mean steady-state volume of distribution was found to be 0.11 +/- 0.01 liters/kg.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7114840      PMCID: PMC182048          DOI: 10.1128/AAC.21.6.935

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Pharmacokinetics of cefazolin compared with four other cephalosporins.

Authors:  W M Kirby; C Regamey
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

2.  Pharmacokinetics of cefamandole using a HPLC assay.

Authors:  N S Aziz; J G Gambertoglio; E T Lin; H Grausz; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

3.  Noncompartmental determination of the steady-state volume of distribution.

Authors:  L Z Benet; R L Galeazzi
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

4.  SK&F 75073, new parenteral broad-spectrum cephalosporin with high and prolonged serum levels.

Authors:  P Actor; J V Uri; I Zajac; J R Guarini; L Phillips; D H Pitkin; D A Berges; G L Dunn; J R Hoover; J A Weisbach
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

5.  Cefonicid: a stable beta-lactamase inhibitor.

Authors:  R J Mehta; D J Newman; B A Bowie; C H Nash; P Actor
Journal:  J Antibiot (Tokyo)       Date:  1981-02       Impact factor: 2.649

6.  Kinetics and renal handling of cefonicid.

Authors:  D Pitkin; J Dubb; P Actor; F Alexander; S Ehrlich; R Familiar; R Stote
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

  6 in total
  11 in total

1.  Pharmacokinetics of cefonicid in children.

Authors:  M Furlanut; R D'Elia; E Riva; F Pasinelli
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

2.  Effect of age and renal function on cefonicid pharmacokinetics.

Authors:  J M Trang; T P Monson; B H Ackerman; F L Underwood; J T Manning; G L Kearns
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

3.  Peritoneal transport of cefonicid.

Authors:  G D Morse; T Lane; D K Nairn; J Deterding; J Curry; P Gal
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

Review 4.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 5.  Pharmacological properties of parenteral cephalosporins: rationale for ambulatory use.

Authors:  E Strehl; F Kees
Journal:  Drugs       Date:  2000       Impact factor: 9.546

Review 6.  Cefonicid. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  E Saltiel; R N Brogden
Journal:  Drugs       Date:  1986-09       Impact factor: 9.546

7.  Pharmacokinetics of cefonicid in patients with skin and skin structure infections.

Authors:  K L Heim-Duthoy; G L Peltier; D R Guay; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

8.  Cefonicid versus clindamycin prophylaxis for head and neck surgery in a randomized, double-blind trial, with pharmacokinetic implications.

Authors:  D Swanson; R A Maxwell; J T Johnson; R L Wagner; V L Yu
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

9.  Pharmacokinetics of cefotiam administered intravenously and intramuscularly to healthy adults.

Authors:  A M Brisson; A Bryskier; L Millerioux; J B Fourtillan
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

10.  Multiple-dose pharmacokinetics of cefonicid in patients with impaired renal function.

Authors:  R T Phelps; J E Conte
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.